Pharmaceutical product development within the Fujifilm Group
Custom manufacturing of specialty chemicals and APIs.
List view / Grid view
News
Johnson & Johnson ordered to pay $8bn in Risperdal case
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
Clinical trial shows cell therapy could be safe for liver disease patients
A new cell therapy has been tested in patients with liver cirrhosis and found no significant adverse effects.
First US state bans ‘pay-for-delay’ pharma practice
California’s state governor has signed a bill which will stop drug makers from paying generic drug producers to stay off the market.
Treatment to increase pain-free light exposure approved
The FDA has approved the first treatment to increase pain-free light exposure in patients with the rare disorder, erythropoietic protoporphyria.
MHRA announces recall of Zantac products made by GSK
The UK MHRA has issued an alert for the recall of unexpired Zantac products made by GSK due to the possible contamination of ranitidine in the medicines.
CQC registers UK clinic to prescribe medical cannabis
The CQC decision marks the first time the agency has accepted a clinic to prescribe patients with medical cannabis in the UK.
New capsule can orally deliver drugs that usually have to be injected
A drug capsule that can carry insulin and protect them from the harsh environment of the gastrointestinal tract has been developed.
Key principles for Canadian essential medicines list
Researchers have found three factors that must be taken into account when compiling an essential medicines list for Canada.
Sir Peter Ratcliffe awarded joint Nobel Prize for Physiology or Medicine
The researcher Sir Peter Ratcliffe and two others have been jointly awarded the Nobel Prize for Physiology or Medicine 2019.
North America leads in number of global pharma partnerships
Research has found that North America had the most strategic partnerships in the pharma industry from 2014 to 2019.
Breakthrough Therapy Designation granted to prostate cancer drug
The FDA has given the designation to niraparib for the treatment of gene-mutated castration-resistant prostate cancer.
CDMO outsourcing market to reach $36.51bn by 2023
The global pharma contract development and manufacturing organisation (CDMO) outsourcing market is predicted to grow.
CMA accuses three pharma companies of illegal market agreement
The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.
Second PrEP preventative HIV treatment approved by FDA
The FDA has announced its approval of Descovy, a PrEP method therapy, to reduce the risk of HIV-1 infection from sex.
